plasma

Apixaban (BMS-562247-01) is an orally active anticoagulant that inhibits coagulation factor Xa, directly preventing the conversion of prothrombin to thrombin and the formation of cross-linked fibrin clots.

APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with inhibition constants (Kis) of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4, respectively, and it effectively prevents kidney injury.

CLP257 is a selective K+-Cl− cotransporter KCC2 activator (EC50: 616 nM) and it is inactive against NKCC1, GABAA receptors, KCC1, KCC3 or KCC4. CLP257 alleviates hypersensitivity in rats with neuropathic painc and it also modulates plasmalemmal KCC2 protein turnover post-translationally. CLP257 restores impaired Cl− transport in neurons with diminished KCC2 activity.

(Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a fatty acid amide hydrolase inhibitor with anti-tumor properties that binds to the plasma membrane, altering lipid organization.

O-Desmethyl gefitinib inhibits EGFR (IC50: 36 nM in subcellular assays). In human plasma, O-Desmethyl gefitinib is an active metabolite of Gefitinib. The formation of O-desmethyl gefitinib is dependent on the CYP2D6 activity.

Torcetrapib (CP-529414) is a cholesteryl ester transfer protein (CETP) inhibitor designed to reduce the heterotypic transfer of cholesteryl ester from HDL to LDL and/or VLDL. It failed in phase III trials due to an excess of deaths.

R59949 is used as a Diacylglycerol kinase (DGK) inhibitor.

L-732138 is a potent and competitive antagonist of neurokinin-1 (NK-1) receptor(IC50 : 2.3 nM)

ELOVL6-IN-2 is a orally active and selective ELOVL6 inhibitor.

Haptoglobin, Phenotype 2-2 is a plasma protein that binds hemoglobin (Hb) to remove free hemoglobin and possesses antioxidant activity. It can be utilized in research related to kidney failure and cardiovascular diseases associated with diabetes.

Plasma kallikrein-IN-5 (Compound 20) is an effective covalent inhibitor of plasma kallikrein (Pka), with an IC50 of 66 nM at 1 minute and 70 pM at 24 hours. It is used in research related to hereditary angioedema (HAE).

Plasma kallikrein-IN-1 is a PKK inhibitor with an IC50 value of 0.5 nM.

Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].

Plasma kallikrein-IN-2, a potent inhibitor of plasma kallikrein (PKal) with an inhibitory concentration (IC) 50 value of 0.1 nM, is utilized in research targeting hereditary angioedema, diabetic macular edema, and diabetic retinopathy.

Alpha 1 Antichymotrypsin, Human Plasma is an inhibitor of serine proteases. This compound is present in amyloid lesions associated with Alzheimer's disease and can be utilized in Alzheimer's research.

Bovine fibrinogen (from fibrinogen) is a natural fibrinogen derived from bovine plasma. It can modulate the activation of NF-KB in endothelial cells and upregulate the expression of the inflammatory chemokine MCP-1.

Fibrinogen (from human plasma) is suitable for preparing production factor solutions.

Fibrinogen from rat plasma can be used for the preparation of growth factor solutions.

Fibronectin (from bovine plasma) plays pivotal roles in various cellular processes including tissue repair, embryogenesis, blood coagulation, and cell migration/adhesion.

Alpha 2 Macroglobulin is an Alpha 2 Macroglobulin. It functions as a broad-spectrum protease inhibitor and also acts as a regulator of extracellular proteolysis, redirecting proteolysis towards small substrates. It is applicable in research related to Alzheimer's disease, inflammation, immunity, and infection.

Alpha 2 Antiplasmin serves as the principal circulating inhibitor of plasmin. This compound plays a crucial role in regulating fibrinolysis within blood vessels.

TOFA-Plasmalogen (compound 1), a derivative of glyceraldehyde, exhibits ferroptosis-inducing properties. This compound promotes lipid peroxidation in cell membranes, leading to cytotoxic effects with an inhibition concentration (IC 50 = 32.87 μM).

Somatostatin 1-28 acetate circulates in human plasma. Approximately 46% of the total somatostatin-like immunoreactivity in plasma is due to Somatostatin 1-28 acetate.

Autotaxin-IN-3 is an inhibitor of Autotaxin (IC50 = 2.4 nM) which is responsible for the increase in lysophosphatidic acid in ascites and plasma.